Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future

1996 ◽  
Vol 1 (6) ◽  
pp. 327-328 ◽  
Author(s):  
OR Hommes ◽  
F Barkhof ◽  
PJH Jongen ◽  
STFM Frequin
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Long Term Effects ◽  
Intravenous Methylprednisolone ◽  
Methylprednisolone Treatment ◽  
Effect Of Treatment

High dose intravenous methylprednisolone treatment is effective and safe in the treatment of relapses in multiple sclerosis, but the long term effects are unclear. Pharmacokinetics are almost unknown, but may be very important for the understanding of the clinical and paraclinical effects. In view of what is known now, IVMP should have a prominent place in basic and clinical MS research.

Suppressive effect of glucocorticoids on TNF-α production is associated with their clinical effect in multiple sclerosis

2010 ◽  
Vol 16 (4) ◽  
pp. 500-502 ◽  
Author(s):  
Lisa ML van Winsen ◽  
Chris H Polman ◽  
Christine D Dijkstra ◽  
Fred JH Tilders ◽  
Bernard MJ Uitdehaag
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Effect ◽  
Suppressive Effect ◽  
High Dose ◽  
Intravenous Methylprednisolone ◽  
Tnf Α ◽  
Before And After ◽  
Effect Of Treatment ◽  
Multiple Sclerosis Patients

A reduced sensitivity to glucocorticoids can affect the clinical effect of treatment with high-dose intravenous methylprednisolone in multiple sclerosis. We prospectively studied 27 multiple sclerosis patients who were treated with intravenous methylprednisolone. Before and after treatment in vitro stimulated TNF-α production in blood cells and the effect of in vitro administered glucocorticoids were determined as a measure of glucocorticoid sensitivity. The suppression of TNF-α production after intravenous methylprednisolone, and the in vitro suppressive effect of glucocorticoids prior to treatment was related to subsequent clinical improvement after intravenous methylprednisolone. The results suggest the existence of a partial glucocorticoid resistance, in a subgroup of multiple sclerosis patients, which may have implications for treatment efficacy.

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations

Neurology ◽  
1986 ◽  
Vol 36 (2) ◽  
pp. 238-238 ◽  
Author(s):  
L. Durelli ◽  
D. Cocito ◽  
A. Riccio ◽  
C. Barile ◽  
B. Bergamasco ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Intravenous Methylprednisolone

scholarly journals Efficacy of cognitive-behavioural psychotherapy in the treatment of chronic fatigue in patients with multiple sclerosis – a literature review

2021 ◽  
Vol 21 (1) ◽  
pp. 36-40
Author(s):  
Justyna Wiśniowska ◽  
◽  
Kamilla Puławska ◽  
Keyword(s):  
Multiple Sclerosis ◽  
Chronic Fatigue ◽  
Research Groups ◽  
Long Term Effects ◽  
Short Term ◽  
Behavioural Model ◽  
Cognitive Behavioural ◽  
The Central Nervous System ◽  
Specific Factors

Fatigue is one of the most common symptoms seen in patients with multiple sclerosis. Cognitive-behavioural psychotherapy can be a non-pharmacological approach for these patients. Van Kessel and Moss-Morris developed a cognitive-behavioural model to explain multiple sclerosis-related fatigue (2006). According to this model, inflammatory and demyelinating factors present in the central nervous system trigger fatigue, while cognitive interpretation, anxiety, or depressive symptoms and resting lifestyle are maintaining factors. Based on the cognitive-behavioural model of fatigue in multiple sclerosis, a protocol encompassing 8 treatment sessions was developed. For over 10 years, studies have been conducted to verify the effectiveness of cognitive-behavioural psychotherapy in the treatment of fatigue in patients with multiple sclerosis. The so far obtained results show that cognitive-behavioural psychotherapy has a moderate short-term effect on reducing fatigue, while the effect size in the long-term is small. The obtained results were undoubtedly influenced by several factors: the heterogeneity of the procedures used, the size of the research groups, and the large number of disease-related intermediary variables. Further research should be conducted to identify specific factors responsible for the effectiveness of cognitive-behavioural psychotherapy in the treatment of fatigue and to assess the long-term effects of therapy.

Long-term effects of T cell vaccination in multiple sclerosis

2003 ◽  
pp. 129-149
Author(s):  
Piet Stinissen ◽  
Guy Hermans ◽  
Niels Hellings ◽  
Robert Medaer ◽  
Jef Raus
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
Long Term Effects ◽  
T Cell Vaccination
Sign in / Sign up

Export Citation Format

Share Document